Anti-neuroinflammatory Effects of Active Compound SPA1413 via Suppression of the MAPK and JAK/STAT Signaling Pathways

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Isoflavones and derivatives exhibit neuroprotective properties against neurological disorders.
• Dehydroequol (SPA1413), derived from S-equol, is a potential anti-amyloidogenic and neuroinflammatory agent for Alzheimer's disease.
• Detailed mechanisms and signaling pathways of SPA1413 remain unelucidated.

Purpose of the Study:

• To identify signaling pathways modulated by SPA1413 in a lipopolysaccharides (LPS)-stimulated BV2 cell model.
• To investigate the anti-neuroinflammatory effects of SPA1413.
• To compare SPA1413's effects with other isoflavone derivatives.

Main Methods:

• Biological assays, Western blotting, and quantitative reverse transcription PCR (qRT-PCR) were employed.
• Lipopolysaccharides (LPS)-stimulated BV2 cells were used as an experimental model.
• Neuronal N2a cells were utilized to assess neuroprotection against LPS-activated microglia.

Main Results:

• SPA1413 suppressed nitric oxide (NO), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and mitogen-activated protein kinase (MAPK) signaling.
• SPA1413 inhibited interleukin-11 (IL-11) via the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway.
• SPA1413 reduced LPS-induced microglial activation, thereby inhibiting neuronal cell death.

Conclusions:

• SPA1413 exerts anti-neuroinflammatory effects by suppressing MAPK and JAK/STAT signaling pathways.
• SPA1413 demonstrates potential as a neuroprotective agent against Alzheimer's disease.
• Further research into isoflavone derivatives like SPA1413 is warranted for neurological disorder treatment.